Breast Cancer : Basic and Clinical Research最新文献

{"title":"Metaplastic Carcinoma of the Axillary Breast With Heterologous Mesenchymal (Chondroid) Differentiation: A Difficult Case and Literature Review.","authors":"Chun-Ming Chang, Ho Yin Pekkle Lam","doi":"10.1177/11782234231215183","DOIUrl":"https://doi.org/10.1177/11782234231215183","url":null,"abstract":"<p><p>Metaplastic breast carcinoma is an invasive carcinoma with a high differentiation rate of the neoplastic epithelium toward mesenchymal-like epithelium. It comprises of only less than 1% of all breast cancers. Although 80% to 90% of metaplastic breast carcinomas are triple-negative cancers, they usually have worse outcomes than other triple-negative breast cancers (TNBCs). Metaplastic carcinoma is also often refractory to cytotoxic chemotherapy. Here, we reported a case of a 61-year-old female patient, presenting with a solitary and pedunculated mass in the right axillary tail breast tissue, whose biopsy revealed metaplastic breast carcinoma with chondroid differentiation. She had failed neoadjuvant chemotherapy and immunotherapy. Although she received debulking surgery, the tumor regrew even faster before surgery. Despite receiving palliative chemotherapy, the patient died 11 weeks after surgery. This case draws attention to physicians that early recognition and surgery may be more beneficial than chemotherapy in combating metaplastic breast carcinoma.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231215183"},"PeriodicalIF":2.9,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138457910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Pathological Complete Response Using Vacuum-Assisted Biopsy in Breast Cancer Patients Who Have Clinical and Radiological Complete Response After Neo-Adjuvant Chemotherapy.","authors":"Siddhant Khare, Irrinki Santosh, Ishita Laroiya, Tulika Singh, Amanjit Bal, Gurpreet Singh","doi":"10.1177/11782234231205698","DOIUrl":"https://doi.org/10.1177/11782234231205698","url":null,"abstract":"<p><strong>Background: </strong>Any treatment protocol that leads to complete elimination of surgery may lead to a better patient acceptance of breast cancer treatments.</p><p><strong>Objectives: </strong>We conducted this study to assess the feasibility of preoperative vacuum-assisted biopsies in identifying pathological complete response (pCR) and its accuracy in correlation to final histopathology report (HPR), in an Indian setting.</p><p><strong>Methods: </strong>This was a prospective study conducted between October 1, 2019, and March 31, 2021. Patients with early breast cancer, estrogen and progesterone receptors negative and either Her2 positive or negative, and who were fit to undergo marker placement at the centre of the tumour and to receive third-generation chemotherapy (4 cycles of 3 weekly doxorubicin and cyclophosphamide followed by 4 cycles of 3 weekly docetaxel) were included in the study. Following the enrolment, a tissue marker was placed at the centre of the tumour and appropriate chemotherapy was started. Patients who achieved clinical complete response were subjected to ultrasound-guided vacuum-assisted biopsy (VAB) from the tumour bed before surgery. Pathology results of the VAB and resected specimen were then compared. Descriptive statistics were used in the study.</p><p><strong>Results: </strong>Eighteen patients were enrolled in the study, with a mean age of 43.6 ± 9.8 years. However, only 10 were eligible for VAB procedure, and sensitivity and specificity were calculated based on the results of these 10 patients only. Vacuum-assisted biopsy showed sensitivity of 50% and specificity of 100% in identifying pCR. Combination of mammography, ultrasonography, and VAB showed sensitivity of 77.8% and specificity of 66.7% in identifying pCR.</p><p><strong>Conclusion: </strong>Vacuum-assisted biopsy of tumour bed may not be sensitive enough to eliminate surgery even in patients who have had exceptional response to neo-adjuvant chemotherapy.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231205698"},"PeriodicalIF":2.9,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138457909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coping in Post-Mastectomy Breast Cancer Survivors and Need for Intervention: Systematic Review.","authors":"Anju Mishra, Jayajith Nair, Anjali Midha Sharan","doi":"10.1177/11782234231209126","DOIUrl":"10.1177/11782234231209126","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most prominent cancer type to affect women. Surgical treatment of invasive breast cancers involves mastectomy. Due to mastectomy, women are subjected to social, emotional, and cultural problems which need to be addressed.</p><p><strong>Objective: </strong>The objective of the study is to understand how women cope with body image-related issues, trauma, anxiety, and depression post-mastectomy.</p><p><strong>Design: </strong>A systematic literature review was conducted for understanding the coping in post-mastectomy patients. The methods for identifying the studies were based on Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) guidelines.</p><p><strong>Databases: </strong>Medline/PubMed, PsycInfo, and Cochrane databases were used for searching relevant articles. A final of 19 studies were analyzed for the work.</p><p><strong>Methods: </strong>Search strings such as \"coping strategies and post mastectomy,\" \"body image coping and post mastectomy\" and \"anxiety coping and post mastectomy\" were used for identification of references from databases. Eligibility criteria were used for finalizing the references.</p><p><strong>Results: </strong>Analysis of the 19 studies has clearly shown that women who undergo mastectomy suffer from anxiety, stress, and trauma. This study has observed that women have problems with their body image post-mastectomy along with bouts of depression. Self-coping has been observed in relatively few studies. Psychological interventions before surgery have been observed to be a better coping strategy. In most of the studies, women opted for breast reconstruction to overcome the trauma associated with mastectomy.</p><p><strong>Conclusion: </strong>Mastectomy has a severe impact on women's appearance and psychology. Breast reconstruction and acceptance have played an important role in coping among these women. However, breast reconstruction is not accepted by many women due to a multitude of factors. Thus, it is essential to have proper intervention programs in place to ensure women can cope with this situation and can lead healthy lives.</p><p><strong>Registration: </strong>Systematic literature review (SLR) is submitted to PROSPERO. The application confirmation number is 449135.Registration awaited from the database.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231209126"},"PeriodicalIF":2.9,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89716912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of Risk-Stratified Breast Cancer Prevention With a Polygenic Risk Score Test in Clinical Practice.","authors":"Peeter Padrik,&nbsp;Mikk Puustusmaa,&nbsp;Neeme Tõnisson,&nbsp;Berit Kolk,&nbsp;Regina Saar,&nbsp;Anna Padrik,&nbsp;Tõnis Tasa","doi":"10.1177/11782234231205700","DOIUrl":"10.1177/11782234231205700","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) screening with mammography reduces mortality but considers currently only age as a risk factor. Personalized risk-based screening has been proposed as a more efficient alternative. For that, risk prediction tools are necessary. Genome-wide association studies have identified numerous genetic variants (single-nucleotide polymorphisms [SNPs]) associated with BC. The effects of SNPs are combined into a polygenic risk score (PRS) as a risk prediction tool.</p><p><strong>Objectives: </strong>We aimed to develop a clinical-grade PRS test suitable for BC risk-stratified screening with clinical recommendations and implementation in clinical practice.</p><p><strong>Design and methods: </strong>In the first phase of our study, we gathered previously published PRS models for predicting BC risk from the literature and validated them using the Estonian Biobank and UK Biobank data sets. We selected the best performing model based on prevalent data and independently validated it in both incident data sets. We then conducted absolute risk simulations, developed risk-based recommendations, and implemented the PRS test in clinical practice. In the second phase, we carried out a retrospective analysis of the PRS test's performance results in clinical practice.</p><p><strong>Results: </strong>The best performing PRS included 2803 SNPs. The C-index of the Cox regression model associating BC status with PRS was 0.656 (SE = 0.05) with a hazard ratio of 1.66. The PRS can stratify individuals with more than a 3-fold risk increase. A total of 2637 BC PRS tests have been performed for women between the ages 30 and 83. Results in clinical use overlap well with expected PRS performance with 5.7% of women with more than 2-fold and 1.4% with more than 3-fold higher risk than the population average.</p><p><strong>Conclusion: </strong>The PRS test separates different BC risk levels and is feasible to implement in clinical practice.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231205700"},"PeriodicalIF":2.9,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/9c/10.1177_11782234231205700.PMC10571698.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41232373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.","authors":"Alan Celik,&nbsp;Tobias Berg,&nbsp;Maj-Britt Jensen,&nbsp;Erik Jakobsen,&nbsp;Hanne Melgaard Nielsen,&nbsp;Iben Kümler,&nbsp;Vesna Glavicic,&nbsp;Jeanette Dupont Jensen,&nbsp;Ann Knoop","doi":"10.1177/11782234231203292","DOIUrl":"10.1177/11782234231203292","url":null,"abstract":"<p><strong>Background: </strong>Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype of breast cancer with poor survival. Currently, the literature lacks comprehensive real-world evidence on locally recurrent and mTNBC patients. To validate the optimal treatment for patients with mTNBC, real-world evidence in combination with data from clinical trials must be evaluated as complementary.</p><p><strong>Objectives: </strong>The objective of the study is to examine outcomes and treatment patterns of patients with advanced triple-negative breast cancer (TNBC) utilizing real-world data of patients from all oncology sites across Denmark.</p><p><strong>Design: </strong>This is a retrospective, non-interventional, multi-site, population-based observational study conducted across all oncology departments in Denmark.</p><p><strong>Methods: </strong>We included all women diagnosed with metastatic or locally recurrent TNBC from January 1, 2017, to December 31, 2019, using the national Danish Breast Cancer Group database. The primary endpoints were overall survival (OS) and progression-free survival (PFS) in the first to third treatment line.</p><p><strong>Results: </strong>The study included 243 women diagnosed with metastatic or recurrent TNBC. The median OS (mOS) was 11.6 months after the first line of treatment, 6.5 months after the second line, and 6.5 months after the third line. De novo mTNBC was associated with shorter OS (mOS: 8.3 vs 14.2 months), and those with a relapse within 18 months of primary diagnosis had shorter OS than those with a relapse after 18 months (mOS: 10.0 vs 18.2). In the first line, taxane was the preferred choice of treatment for patients with de novo mTNBC, whereas capecitabine was preferred for patients with recurrent TNBC.</p><p><strong>Conclusions: </strong>This real-world, nationwide study demonstrated poor OS among patients with metastatic or recurrent TNBC, with a mOS of 11.6 months (95% CI, 9.9-17.3). Patients who presented with de novo mTNBC or who had a relapse of their breast cancer within 18 months of primary diagnosis had shorter OS.</p><p><strong>Registration: </strong>The study was registered and approved by the Danish Capital Regions research overview (P-2021-605).</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231203292"},"PeriodicalIF":2.9,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/08/10.1177_11782234231203292.PMC10552450.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41107546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Homologous Recombination Abnormalities Associated With <i>BRCA1/2</i> Mutations as Predicted by Machine Learning of Targeted Next-Generation Sequencing Data.","authors":"Maher Albitar,&nbsp;Hong Zhang,&nbsp;Andrew Pecora,&nbsp;Stanley Waintraub,&nbsp;Deena Graham,&nbsp;Mira Hellmann,&nbsp;Donna McNamara,&nbsp;Ahmad Charifa,&nbsp;Ivan De Dios,&nbsp;Wanlong Ma,&nbsp;Andre Goy","doi":"10.1177/11782234231198979","DOIUrl":"https://doi.org/10.1177/11782234231198979","url":null,"abstract":"<p><strong>Background: </strong>Homologous recombination deficiency (HRD) is the hallmark of breast cancer gene 1/2 (<i>BRCA1/2</i>)-mutated tumors and the unique biomarker for predicting response to double-strand break (DSB)-inducing drugs. The demonstration of HRD in tumors with mutations in genes other than <i>BRCA1/2</i> is considered the best biomarker of potential response to these DSB-inducer drugs.</p><p><strong>Objectives: </strong>We explored the potential of developing a practical approach to predict in any tumor the presence of HRD that is similar to that seen in tumors with <i>BRCA1/2</i> mutations using next-generation sequencing (NGS) along with machine learning (ML).</p><p><strong>Design: </strong>We use copy number alteration (CNA) generated from routine-targeted NGS data along with a modified naïve Bayesian model for the prediction of the presence of HRD.</p><p><strong>Methods: </strong>The CNA from NGS of 434 targeted genes was analyzed using CNVkit software to calculate the log2 of CNA changes. The log2 values of various sequencing reads (bins) were used in ML to train the system on predicting tumors with <i>BRCA1/2</i> mutations and tumors with abnormalities similar to those detected in <i>BRCA1/2</i> mutations.</p><p><strong>Results: </strong>Using 31 breast or ovarian cancers with <i>BRCA1/2</i> mutations and 84 tumors without mutations in any of 12 homologous recombination repair (HRR) genes, the ML demonstrated high sensitivity (90%, 95% confidence interval [CI] = 73%-97.5%) and specificity (98%, 95% CI = 90%-100%). Testing of 114 tumors with mutations in HRR genes other than <i>BRCA1/2</i> showed 39% positivity for HRD similar to that seen in <i>BRCA1/2</i>. Testing 213 additional wild-type (WT) cancers showed HRD positivity similar to <i>BRCA1/2</i> in 32% of cases. Correlation with proportional loss of heterozygosity (LOH) as determined using whole exome sequencing of 51 samples showed 90% (95% CI = 72%-97%) concordance. The approach was also validated in an independent set of 1312 consecutive tumor samples.</p><p><strong>Conclusions: </strong>These data demonstrate that CNA when combined with ML can reliably predict the presence of <i>BRCA1/2</i> level HRD with high specificity. Using <i>BRCA1/2</i> mutant cases as gold standard, this ML can be used to predict HRD in cancers with mutations in other HRR genes as well as in WT tumors.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231198979"},"PeriodicalIF":2.9,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/c3/10.1177_11782234231198979.PMC10542224.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41103801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of Hepatic Metastatic Disease in Patients with Stage IV Breast Cancer Is Similar for Steatotic and Non-Steatotic Livers.","authors":"Adeel Haq, Tyler J Fraum, Yu Tao, Farrokh Dehdashti, Maverick LeBlanc, Mark J Hoegger, Jingqin Luo, Katherine Weilbaecher, Lindsay L Peterson","doi":"10.1177/11782234231166476","DOIUrl":"10.1177/11782234231166476","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common non-cutaneous malignancy and the second leading cause of cancer mortality in the United States. Breast cancer is a heterogeneous disease; diagnosis at an early stage renders it potentially curable, whereas advanced metastatic disease carries a worse prognosis.</p><p><strong>Objectives: </strong>To investigate whether hepatic steatosis (HS) is associated with liver metastases in patients with newly diagnosed stage IV female breast cancer patients (either de novo metastatic breast cancer or recurrent metastatic breast cancer) using non-contrast computed tomography (CT) as a marker of HS.</p><p><strong>Design: </strong>Retrospective analysis.</p><p><strong>Methods: </strong>We retrospectively identified 168 patients with stage IV breast cancer with suitable imaging from a prospectively maintained oncologic database. Three radiologists manually defined hepatic regions of interest on non-contrast CT images, and attenuation data were extracted. HS was defined as a mean attenuation <48 Hounsfield units. The frequency of hepatic metastatic disease was calculated for patient with and without HS. Relationships between HS and various patient (age, body mass index, race) and tumor (hormone receptor status, HER2 status, tumor grade) characteristics were also analyzed.</p><p><strong>Results: </strong>There were 4 patients with liver metastasis in the HS group (41 patients) versus 20 patients with liver metastases in the non-HS group (127 patients). The difference in frequencies of liver metastases among patients with (9.8%) versus without (15.7%) hepatic steatosis (odds ratio = 1.72 [0.53-7.39]) was not statistically significant (<i>P</i> = .45). Body mass index was significantly higher (<i>P</i> = .01) among patients with hepatic steatosis (32.2 ± 7.3 vs 28.8 ± 7.1 kg/m²). Otherwise, there were no significant differences between patients with versus without HS with respect to regarding age, race, hormone receptor status, HER2 status, or tumor grade.</p><p><strong>Conclusion: </strong>The frequency of hepatic metastatic disease in patients with stage IV breast cancer is similar for steatotic and non-steatotic livers.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231166476"},"PeriodicalIF":2.9,"publicationDate":"2023-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/e2/10.1177_11782234231166476.PMC10170590.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Effects of Indirect Coculture of Human Mesenchymal Stem Cells on the Migration of Breast Cancer Cells: A Systematic Review and Meta-Analysis.","authors":"Marie-Juliet Brown, Mhairi A Morris, Elizabeth C Akam","doi":"10.1177/11782234221145385","DOIUrl":"10.1177/11782234221145385","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is the most diagnosed cancer and the leading cause of cancer death in women globally, and mesenchymal stem cells have been widely implicated in tumour progression. This systematic review and meta-analysis seeks to identify and summarise existing literature on the effects of human mesenchymal stem cells (hMSCs) on the migration of breast cancer cells (BCCs) in vitro, to determine the direction of this relationship according to existing research and to identify the directions for future research.</p><p><strong>Methods: </strong>A systematic literature search was conducting using a collection of databases, using the following search terms: in vitro AND mesenchymal stem cells AND breast cancer. Only studies that investigated the effects of human, unmodified MSCs on the migration of human, unmodified BCCs in vitro were included. Standardised mean differences (SMDs) were calculated to determine pooled effect sizes.</p><p><strong>Results: </strong>This meta-analysis demonstrates that hMSCs (different sources combined) increase the migration of both MDA-MB-231 and MCF-7 cell lines in vitro (SMD = 1.84, <i>P</i> = .03 and SMD = 2.69, <i>P</i> < .00001, respectively). Importantly, the individual effects of hMSCs from different sources were also analysed and demonstrated that MSCs derived from human adipose tissue increase BCC migration (SMD = 1.34, <i>P</i> = .0002) and those derived from umbilical cord increased both MDA-MB-231 and MCF-7 migration (SMD = 3.93, <i>P</i> < .00001 and SMD = 3.01, <i>P</i> < .00001, respectively).</p><p><strong>Conclusions: </strong>To our knowledge, this is the first systematic review and meta-analysis investigating and summarising the effects of hMSCs from different sources on the migration of BCCs, in vitro.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234221145385"},"PeriodicalIF":1.8,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/5f/10.1177_11782234221145385.PMC9875320.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10639160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates.","authors":"Daniel González-Hurtado,&nbsp;Sergio Rivero,&nbsp;Juan Carlos Samamé Pérez-Vargas,&nbsp;Fernando E Petracci","doi":"10.1177/11782234231192780","DOIUrl":"https://doi.org/10.1177/11782234231192780","url":null,"abstract":"<p><p>Prognostic and predictive factors for early and late distant distance recurrence risk in estrogen-receptor positive and HER2-receptor negative early breast cancer are well known, but not all these variables work equally for the prediction. The following are the most widely accepted variables for categorizing risk levels: clinic-pathologic features (tumor size, lymph node involvement, histological grade, age, menopausal status, Ki-67 expression, estrogen, and progesterone expression), primary systemic treatment response (pathologic response and/or Ki-67 downstaging), and gene expression signatures stratification. Treatment guidelines from cancer societies and collaborative groups, online predict-tools, real-world data and experts' opinion recommends different adjuvant strategies (chemotherapy, endocrine therapy, ovarian suppression, olaparib, or abemaciclib) depending on the low (< 10%), intermediate (10%-20%) or high-risk of distance recurrence at least in the first 5 years. Multiple randomized prospective trials were updated in 2022, that evidence allow us to perform a stratification of risk in pre- and postmenopausal women with estrogen-receptor positive and HER2-receptor negative early breast cancer based on a combination of clinic-pathologic features and genomic assays and guide the adjuvant systemic treatment recommendation for those with high risk.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231192780"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/1c/10.1177_11782234231192780.PMC10450458.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>TP53</i> Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease.","authors":"Shin Takahashi,&nbsp;Keiju Sasaki,&nbsp;Chikashi Ishioka","doi":"10.1177/11782234231167655","DOIUrl":"https://doi.org/10.1177/11782234231167655","url":null,"abstract":"<p><strong>Background: </strong>The <i>TP53</i> signature that predicts the mutation status of <i>TP53</i> has been shown to be a prognostic factor and predictor of neoadjuvant chemotherapy (NAC) response.</p><p><strong>Objectives: </strong>The current study sought to investigate the utility of the <i>TP53</i> signature for predicting pathological complete response (pCR) and its prognostic significance among patients with residual disease (RD).</p><p><strong>Design: </strong>The study followed a retrospective cohort study design.</p><p><strong>Methods: </strong>Patients with T1-3/N0-1 from a cohort of those with HER2-negative breast cancer who received NAC were selected. Ability to predict pCR was evaluated using odds ratio, positive and negative predictive values, sensitivity, and specificity. Prognostic factors in the RD group were explored using the Cox proportional hazards model with distant recurrence-free survival (DRFS). Four independent cohorts were used for validation.</p><p><strong>Results: </strong>A total of 333 eligible patients were classified into the <i>TP53</i> mutant signature (n = 154) and wild-type signature (n = 179). Among the molecular and pathological factors, the <i>TP53</i> signature had the highest predictive power for pCR. In 4 independent cohorts (n = 151, 85, 104, and 67, respectively), pCR rate in <i>TP53</i> mutant signature group was significantly higher than that in the wild-type group. Univariate and multivariate analyses on DRFS in the RD group identified the <i>TP53</i> signature and nodal status as independent prognostic factors, with the former having a better hazard ratio than the latter. After comparing DRFS between 3 groups (pCR, RD/<i>TP53</i> wild-type signature, and RD/<i>TP53</i> mutant signature groups), the RD/<i>TP53</i> mutant signature group showed significantly worse prognosis compared with others. The RD/<i>TP53</i> wild-type signature group did not exhibit inferior DRFS compared with the pCR group.</p><p><strong>Conclusion: </strong>Our results showed that the <i>TP53</i> mutant signature can predict pCR and that combining pathological response and <i>TP53</i> mutant signature allows for the identification of subgroups with truly poor prognosis.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231167655"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/26/10.1177_11782234231167655.PMC10170595.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10290147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}